The filing confirms OKYO has sufficient capital to initiate and complete the NEPTUNE Phase 3 trial. The key catalyst to watch is the trial initiation in H2 2026 and subsequent enrollment updates. No new clinical data was released, so the stock may trade on the existing Phase 3 narrative and cash runway rather than this filing alone.
Price Chart
Executive Summary
OKYO Pharma filed its annual report (20-F) for FY2026 ended March 31, 2026, alongside a 6-K press release highlighting a strengthened cash position of ~$20.6M and accelerated Phase 3 plans for lead candidate urcosimod in neuropathic corneal pain (NCP). The company reported a net loss of $8.95M (vs $4.71M in FY2025) and no revenue, but raised ~$22M in a February 2026 public offering to fund the upcoming NEPTUNE Phase 3 pivotal trial. The filing confirms FDA alignment on a single-trial registration pathway and Fast Track designation, but provides no new clinical data.
Key Facts
- Cash and cash equivalents plus short-term investments of $20.6M as of March 31, 2026
- Net loss for FY2026: $8,949,657 (FY2025: $4,706,292)
- Raised ~$22M in gross proceeds from February 2026 public offering
- Phase 3 NEPTUNE trial for urcosimod planned for H2 2026, enrolling ~111 patients, 2:1 randomization
- FDA Fast Track designation and positive Type D meeting supporting potential single-trial approval pathway
- No revenue generated; accumulated deficit of $152M
- R&D expenses decreased to $1.8M from $2.3M in prior year
- 52,479,527 ordinary shares outstanding as of July 15, 2026
Financial Impact
Cash position of $20.6M provides runway through Phase 3 completion; net loss increased to $8.95M from $4.71M; no revenue.
Risk Factors
- Phase 3 trial failure or delay could deplete cash and impair stock value
- No revenue and ongoing losses require future capital raises, likely dilutive
- Competition from existing and pipeline therapies for NCP and dry eye disease
- Regulatory approval not guaranteed despite Fast Track designation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 15 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (OKYO) — Batch item 1 | 0001493152-26-033850 |
| Exhibit: ex99-1.htm | 0001493152-26-033847 |
| Document: 0001493152-26-033850-index-headers.html | 0001493152-26-033850 |
| Document: 0001493152-26-033850-index.html | 0001493152-26-033850 |
| Document: 0001493152-26-033850.txt | 0001493152-26-033850 |
| 20-F Filing (OKYO) — Batch item 6 | 0001493152-26-033847 |
| Exhibit: ex19-1.htm | 0001493152-26-033850 |
| Exhibit: ex12-1.htm | 0001493152-26-033850 |
| Exhibit: ex12-2.htm | 0001493152-26-033850 |
| Exhibit: ex13-2.htm | 0001493152-26-033850 |
| Exhibit: ex13-1.htm | 0001493152-26-033850 |
| Exhibit: ex15-1.htm | 0001493152-26-033850 |
| Document: 0001493152-26-033847-index-headers.html | 0001493152-26-033850 |
| Document: 0001493152-26-033847-index.html | 0001493152-26-033850 |
| Document: 0001493152-26-033847.txt | 0001493152-26-033850 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.45 (−0.68%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.45 (−0.68%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.45 (+6.62%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.45 (−5.23%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.45 (−7.64%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.45 (−11.59%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.45 (−11.59%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.45 (−2.03%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.45 (−2.03%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.45 (−2.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers